CA2665026A1 - Administration de precurseurs de dopa combines a des sources de dopa en vue d'obtenir des resultats optimaux avec les neurotransmetteurs de catecholamine - Google Patents
Administration de precurseurs de dopa combines a des sources de dopa en vue d'obtenir des resultats optimaux avec les neurotransmetteurs de catecholamine Download PDFInfo
- Publication number
- CA2665026A1 CA2665026A1 CA002665026A CA2665026A CA2665026A1 CA 2665026 A1 CA2665026 A1 CA 2665026A1 CA 002665026 A CA002665026 A CA 002665026A CA 2665026 A CA2665026 A CA 2665026A CA 2665026 A1 CA2665026 A1 CA 2665026A1
- Authority
- CA
- Canada
- Prior art keywords
- dopa
- dopamine
- precursor
- patient
- neurotransmitter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims abstract description 120
- 239000002858 neurotransmitter agent Substances 0.000 title claims abstract description 92
- 239000002243 precursor Substances 0.000 title claims abstract description 79
- 150000003943 catecholamines Chemical class 0.000 title claims abstract description 33
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 190
- 229960003638 dopamine Drugs 0.000 claims abstract description 95
- 238000000034 method Methods 0.000 claims abstract description 44
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000004064 dysfunction Effects 0.000 claims abstract description 17
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 84
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 64
- 229940076279 serotonin Drugs 0.000 claims description 42
- 229940109239 creatinine Drugs 0.000 claims description 32
- 238000003556 assay Methods 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 29
- 238000003786 synthesis reaction Methods 0.000 abstract description 29
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract description 14
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 abstract description 13
- 229960001682 n-acetyltyrosine Drugs 0.000 abstract description 13
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract description 11
- 241000122904 Mucuna Species 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 description 27
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 26
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 26
- 229960004441 tyrosine Drugs 0.000 description 21
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 15
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 13
- 229930182837 (R)-adrenaline Natural products 0.000 description 13
- 229960005139 epinephrine Drugs 0.000 description 13
- 238000012773 Laboratory assay Methods 0.000 description 12
- 229960005190 phenylalanine Drugs 0.000 description 11
- 230000002485 urinary effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000037361 pathway Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 230000009123 feedback regulation Effects 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- -1 tryosine Chemical compound 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81184406P | 2006-06-08 | 2006-06-08 | |
| US60/811,844 | 2006-06-08 | ||
| US11/759,732 US20070293571A1 (en) | 2006-06-08 | 2007-06-07 | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
| US11/759,732 | 2007-06-07 | ||
| PCT/US2007/013596 WO2007146174A2 (fr) | 2006-06-08 | 2007-06-08 | Administration de précurseurs de dopa combinés à des sources de dopa en vue d'obtenir des résultats optimaux avec les neurotransmetteurs de catécholamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2665026A1 true CA2665026A1 (fr) | 2007-12-21 |
Family
ID=38832427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002665026A Abandoned CA2665026A1 (fr) | 2006-06-08 | 2007-06-08 | Administration de precurseurs de dopa combines a des sources de dopa en vue d'obtenir des resultats optimaux avec les neurotransmetteurs de catecholamine |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20070293571A1 (fr) |
| EP (1) | EP2028935A2 (fr) |
| CA (1) | CA2665026A1 (fr) |
| WO (1) | WO2007146174A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011047412A1 (fr) * | 2009-10-22 | 2011-04-28 | The Heart Research Institute Ltd | Tyrosine et l-dopa pour réduire l'incorporation de l-dopa dans des protéines |
| US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
| CN108546237A (zh) * | 2018-06-15 | 2018-09-18 | 那坡康正天然植物提取有限责任公司 | 一种以猫豆为原料提取左旋多巴的方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097947A (en) * | 1961-01-30 | 1963-07-16 | Mend Johnson & Company | Nutritional composition and process |
| US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
| US4237118A (en) * | 1972-03-06 | 1980-12-02 | Howard Alan N | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| US4397866A (en) * | 1979-05-07 | 1983-08-09 | Massachusetts Institute Of Technology | Process for increasing glycine levels in the brain and spinal cord |
| US4377595A (en) * | 1979-08-13 | 1983-03-22 | Massachusetts Institute Of Technology | Process for reducing depression |
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US4596807A (en) * | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5011608A (en) * | 1988-11-18 | 1991-04-30 | Dragana Damjanovic | Biogenic amine assay using HPLC-ECD |
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| US5019594A (en) * | 1989-11-28 | 1991-05-28 | Interneuron Pharmaceuticals, Inc. | Method for decreasing appetite |
| EP0533818B1 (fr) * | 1990-06-13 | 1997-12-17 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Procede d'activation de la reproduction d'animaux d'elevage saisonnier par administration de l-dihydroxyphenylalanine (l-dopa) |
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| US5480657A (en) * | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
| US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| ES2177654T3 (es) * | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| WO1998001157A1 (fr) * | 1996-07-05 | 1998-01-15 | The Wwk Trust | Composition pour le traitement des neuropathies peripheriques contenant des antidepresseurs et/ou des inhibiteurs de monoamins-oxidase et/ou de la vitamine b12 et/ou un precurseur ou inducteur d'un neurotransmetteur |
| US20010020007A1 (en) * | 1996-08-26 | 2001-09-06 | Oswald Wiss | Vitamin preparations for reducing oxygen consumption during physical efforts |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| WO1998046248A1 (fr) * | 1997-04-14 | 1998-10-22 | Anderson Byron E | Methode et matiere destinees a l'inhibition du complement |
| US20010002269A1 (en) * | 1997-05-06 | 2001-05-31 | Zhao Iris Ginron | Multi-phase food & beverage |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| US5939076A (en) * | 1997-11-12 | 1999-08-17 | Allocca Techical, Inc. | Composition and method for treating or alleviating migraine headaches |
| US6123729A (en) * | 1998-03-10 | 2000-09-26 | Bristol-Myers Squibb Company | Four compartment knee |
| US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| EP1158973B1 (fr) * | 1999-02-24 | 2005-05-04 | University Of Cincinnati | Traitement des troubles du controle des impulsions a base de derives sulfamates |
| US6261589B1 (en) * | 1999-03-02 | 2001-07-17 | Durk Pearson | Dietary supplement nutrient soft drink composition with psychoactive effect |
| US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| US6955873B1 (en) * | 2000-08-04 | 2005-10-18 | Kenneth Blum | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors |
| DE29923436U1 (de) * | 1999-09-18 | 2000-09-07 | Utility Consult Hinzmann & König OHG, 20249 Hamburg | Verbrauchszähler für flüssige und gasförmige Medien |
| US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| US20020147206A1 (en) * | 2001-04-05 | 2002-10-10 | Pfizer Inc. | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |
| US6541043B2 (en) * | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| US8142799B2 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | High potency clinical anti-craving treatment and method of use |
| CA2479218A1 (fr) * | 2002-03-21 | 2003-10-02 | Martin C. Hinz | Technologie d'optimisation d'un segment de systeme de serotonine et catecholamine |
| US20060110325A1 (en) * | 2003-02-21 | 2006-05-25 | Hinz Martin C | Serotonin and catecholamine segment optimization technology |
| US20040077556A1 (en) * | 2002-04-22 | 2004-04-22 | Robert Chinery | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US20040071681A1 (en) * | 2002-10-10 | 2004-04-15 | Lydia Muller | Method and composition for reducing cravings for a craved substance |
| US20040116351A1 (en) * | 2002-12-06 | 2004-06-17 | Fast Balance, Inc. | Method for enhancing the natural reward system for exercise |
| US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
| BRPI0407619A (pt) * | 2003-02-21 | 2006-03-01 | Martin C Hinz | tecnologia de otimização de segmento de sistema serotonina e catecolamina |
| US20050233014A1 (en) * | 2004-03-02 | 2005-10-20 | Lee Steve S | Methods for affecting homeostasis and metabolism in a mammalian body |
| US20060062859A1 (en) * | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
-
2007
- 2007-06-07 US US11/759,732 patent/US20070293571A1/en not_active Abandoned
- 2007-06-08 EP EP07795941A patent/EP2028935A2/fr not_active Withdrawn
- 2007-06-08 WO PCT/US2007/013596 patent/WO2007146174A2/fr not_active Ceased
- 2007-06-08 CA CA002665026A patent/CA2665026A1/fr not_active Abandoned
-
2009
- 2009-03-09 US US12/400,291 patent/US20090234012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007146174A3 (fr) | 2008-11-20 |
| WO2007146174A2 (fr) | 2007-12-21 |
| US20070293571A1 (en) | 2007-12-20 |
| US20090234012A1 (en) | 2009-09-17 |
| EP2028935A2 (fr) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wegener et al. | Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo | |
| Storga et al. | Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients | |
| Carboni et al. | Effect of amphetamine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats. An in vivo microdyalisis study | |
| Kennaway et al. | Melatonin and circadian rhythms | |
| Mathew et al. | Ketamine for treatment-resistant unipolar depression: current evidence | |
| US20080241278A1 (en) | Serotonin and catecholamine system segment optimization technology | |
| Goldstein et al. | Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3, 4-dihydroxyphenylacetaldehyde in PC12 cells | |
| Parry | The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications | |
| WO2009004082A2 (fr) | Compositions pharmaceutiques anticonvulsives | |
| Pascucci et al. | In vivo catecholaminergic metabolism in the medial prefrontal cortex of ENU2 mice: an investigation of the cortical dopamine deficit in phenylketonuria | |
| Perlow et al. | The circadian variation of catecholamine metabolism in the subhuman primate | |
| CA2665026A1 (fr) | Administration de precurseurs de dopa combines a des sources de dopa en vue d'obtenir des resultats optimaux avec les neurotransmetteurs de catecholamine | |
| Youngstedt et al. | Melatonin excretion is not related to sleep in the elderly | |
| Santiago et al. | In vivo release of dopamine from rat striatum, substantia nigra and prefrontal cortex: differential modulation by baclofen | |
| Cansev et al. | 4 aromatic amino acids in the brain | |
| Feitosa et al. | Thyroid hormones may influence cortical bone healing around titanium implants: a histometric study in rats | |
| Swerdlow | Is NADH effective in the treatment of Parkinson’s disease? | |
| US20040229285A1 (en) | Serotonin and catecholamine system segment optimization technology | |
| Kaseda et al. | Effect of selegiline on dopamine concentration in the striatum of a primate | |
| Kugelberg et al. | Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats | |
| Brodnik et al. | Increased tyrosine availability increases brain regional DOPA levels in vivo | |
| Hughes et al. | Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences | |
| US20060110325A1 (en) | Serotonin and catecholamine segment optimization technology | |
| Jaskiw et al. | Clozapine-induced dopamine release in the medial prefrontal cortex is augmented by a moderate concentration of locally administered tyrosine but attenuated by high tyrosine concentrations or by tyrosine depletion | |
| Sourkes | How dopamine was recognised as a neurotransmitter: a personal view |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |